Drug intelligence / Profile preview

alprazolam + escitalopram

Development stage
Unknown
Lead developer
Lundbeck
Modality
Small Molecules
Administration
Oral
01

Overview

Alprazolam + escitalopram is a combination of two pharmaceutical drugs used primarily in the management of anxiety and depressive disorders. Alprazolam is a benzodiazepine that acts as a central nervous system depressant by enhancing the effect of gamma-aminobutyric acid (GABA), leading to sedative, anxiolytic, and muscle relaxant properties. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the brain by inhibiting its reabsorption, thereby improving mood and reducing symptoms of depression and anxiety. While both medications can be effective for their respective indications, their concurrent use can lead to additive effects on sedation, cognitive impairment, and other central nervous system side effects. This combination should only be used under careful medical supervision due to potential risks such as over-sedation, increased risk of falls (especially in elderly patients), cognitive impairment, dependence (primarily from alprazolam), and exacerbation of overlapping side effects[1][3][6].

Other names
Xanax + Lexapro
02

Targets

GABRR (GABA-A receptor subunit rho)SERT allosteric site (Serotonin transporter allosteric site)

Beyond the preview

Go deeper on alprazolam + escitalopram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on alprazolam + escitalopram.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call